Sanofi Pasteur Biologics, LLC

Sanofi Pasteur Inc.

Other

Simon Delagrave

Stephen F Anderson

Sophia Mundle

John Hamberger

Farshad Guirakhoo

Alexander A Rumyantsev

Harold Kleanthous

Nausheen Rahman

CharChang Lai

Qinglian Li

Nathan Brown

Rachid Oubelaid

Stephen Anderson

Caroline Maier

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

Herpesvirus compositions and related methods

Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.

ICP0-mediated enhanced expression system

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion exchange chromatography and tangential flow filtration.

Purification of herpes virus

The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.

Compositions and methods for the production of alpha-herpesviruses

This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.

Recombinant bicistronic flavivirus vectors

This invention relates to chimeric flavivirus vectors that can be used, for example, in the prevention and treatment of influenza virus infection, compositions including such viral vectors, and methods employing the vectors.

Flavivirus vaccine vector against influenza virus

[object Object]

The present invention provides polypeptides that contain one or more PDZ loop-variants and are useful in the detection of pathogens and disease-associated molecules. The polypeptides of the invention are also useful in the diagnosis, treatment, and prevention of diseases. Also provided are methods of preparing polypeptides of the invention.

Growing community of inventors

Cambridge, MA, United States of America

Simon Delagrave